News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Lucy Scientific Discovery, Inc. Successfully Acquires Wesana Health Assets
Thursday, July 06, 2023Lucy Scientific Discovery Inc NASDAQ LSDI has successfully completed its acquisition of Wesana Health Incs SANA assets marking a significant milestone in the field of mental health therapeutics This acquisition strengthens Lucys position as a leader...
Zenocutuzumab (Zeno) Has Been Granted a Second Breakthrough Therapy Designation by the U.s. Food & Drug Administration
Thursday, July 06, 2023Merus NV a company focused on oncology research and development has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy Designation BTD for their drug zenocutuzumab Zeno The designation is for the treatment of adva...
European Commission Grants Approval for ORKAMBI® (Lumacaftor/ivacaftor) in the Treatment of Cystic Fibrosis in Children Aged 1 to <2 Years
Thursday, July 06, 2023Vertex Pharmaceuticals announced today that the European Commission has granted approval for the label extension of ORKAMBI lumacaftorivacaftor for the treatment of children with cystic fibrosis CF aged to under years old who have two copies of the...
Sorrento Presents Positive Phase IIa Study Findings of Abivertinib for Relapsed/refractory Marginal Zone Lymphoma (R/R MZL) and Reveals Plan for Crucial Phase III Trial
Thursday, July 06, 2023Sorrento Therapeutics Inc OTC SRNEQ has released positive findings from a phase IIa study conducted in China on Abivertinib a dual inhibitor targeting mutant EGFR and BTK Abivertinib a pyrrolopyrimidinebased drug has shown potential in multiple indic...
Oxford Biotherapeutics Launches Phase Ib Clinical Trial for OBT076 in Patients With Advanced Solid Tumors, Initiating First Patient Dose With CPI Balstilimab in Europe
Wednesday, July 05, 2023Oxford BioTherapeutics OBT has recently initiated a Phase b combination trial to evaluate its lead candidate OBT in conjunction with Agenus balstilimab an antiPD checkpoint inhibitor The trial is being conducted at multiple centers in Europe specific...
Kashiv Biosciences Announces Positive Phase 1 Study Outcomes for ADL018, a Biosimilar Candidate for Xolair® (Omalizumab)
Wednesday, July 05, 2023Kashiv Biosciences LLC Kashiv or the Company has announced the successful completion of a Phase clinical study for ADL a biosimilar candidate to Xolair omalizumab in healthy volunteers
Journey Medical Corporation to Reveal Phase 3 Trial Findings for DFD-29 in Papulopustular Rosacea Treatment Around July 10, 2023
Tuesday, July 04, 2023Journey Medical Corporation Nasdaq DERM has made an announcement regarding the upcoming release of the topline results for its Phase clinical trials of DFD a potential treatment for moderate to severe papulopustular rosacea PPR
Infant Bacterial Therapeutics' New Product Receives FDA Orphan Drug Designation
Tuesday, July 04, 2023IBT has received orphan drug designation from the FDA for their product IBP which is intended for the treatment of gastroschisis Gastroschisis is a rare condition in infants that poses risks such as growth retardation sepsis and NEC often resulting i...
NLS Pharmaceutics Receives FDA Review and IRB Approval for Full Study Protocol, Advances Phase 3 Clinical Program (AMAZE) for Mazindol Er in the Treatment of Narcolepsy
Tuesday, July 04, 2023NLS Pharmaceutics Ltd Nasdaq NLSP has made significant announcements regarding the development of their drug Mazindol ER for narcolepsy type The US Food and Drug Administration FDA has thoroughly reviewed the NLS study protocol which is part of the...
Scisparc Granted Approval for Phase IIb Clinical Trial of Novel Treatment SCI-110 for Tourette Syndrome in Germany
Monday, July 03, 2023SciSparc Ltd Nasdaq SPRC a clinicalstage pharmaceutical company specializing in therapies for central nervous system disorders has received approval from the Federal Institute for Drugs and Medical Devices in Germany BfArM to conduct a Phase IIb clin...
